New drug shows promise in shrinking ovarian tumors before surgery
NCT ID NCT03943173
First seen Jun 24, 2026 · Last updated Jun 27, 2026 · Updated 1 time
Summary
This early trial is testing whether the drug olaparib can shrink tumors in people with newly diagnosed BRCA-mutant ovarian, fallopian tube, or peritoneal cancer before they have surgery. Fifteen participants will receive olaparib for two cycles, then undergo standard chemotherapy and surgery. The main goal is to see if this approach is feasible and safe, and to measure how well the tumors respond.
What this could mean
Our plain-language read of the trial. This is informational only — not medical advice or a prediction.
- Active substance
- Olaparib (a PARP inhibitor drug)
- What this could lead to
- If successful, this could show that giving olaparib before surgery helps control BRCA-mutant ovarian cancer, potentially leading to better treatment approaches.
- What could go wrong
- This is a very early (Phase 1) trial with only 15 participants, so results may not apply widely. Olaparib can cause side effects like fatigue, nausea, and blood cell changes.
This is an AI summary of the original study and may miss details. Read our disclaimer.
Get updates
Get notified about this study
Sign up to get updates when this study changes or when new studies for BRCA-MUTATED OVARIAN CARCINOMA are added.
By submitting, you agree to our Terms of use
Conditions
The condition(s) this trial relates to.
As listed by the trial registrant
The condition terms exactly as the trial's registrant entered them.
Contacts and locations
Show contact details
Enter your email to view the contact information for this study.
By submitting, you agree to our Terms of use
Locations
-
M D Anderson Cancer Center
Houston, Texas, 77030, United States
More trials for these conditions
Other studies related to the condition(s) this trial covers.
- Immune-Boosting drug combo takes on Hard-to-Treat ovarian cancer
- New drug combo aims to shrink Hard-to-Treat pancreatic and ovarian tumors
- Engineered immune cells take aim at Hard-to-Treat cancers
- Family genetic testing could prevent ovarian cancer
- Cancer drug niraparib tested before prostate surgery – early trial stopped
- Keytruda takes on genetic weak spots in advanced tumors